Journals / Turkish Journal of Hematology / 2011 / Cilt: 28 - Sayı: 4

Kronik myeloproliferatif hastalık tanılı hastalarda Factor V 1691A (Leiden) ve protrombin G20210A gen mutasyonu ve tromboz

Factor V G1691A (Leiden) and prothrombin G20210A gene mutation status, and thrombosis in patients with chronic myeloproliferative disorders

Pages
306–311
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hepatic vein thrombosis was noted in 3 patients that had FVL mutation, of which 1 also had PT mutation.Conclusion: We did not observe a relationship between thrombosis, and FVL or PT mutations in CMPD patients; however, 3 of the patients that had hepatic vein thrombosis also had FVL mutation.Larger studies are needed to more clearly determine if all CMPD patients with hepatic vein thrombosis need be investigated for FVL and PT mutation.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study was to examine Factor V G1691A (Leiden) (FVL) and prothrombin G20210A (PT) gene mutation status, and their relationship with thrombosis in patients with chronic myeloproliferative disorders (CMPDs).
📊
Key Findings & Data:Materials and Methods: The study included 160 patients with a CMPD that were regularly followed-up between 1993 and 2009.
💡
Conclusion & Impact:Hepatic vein thrombosis was noted in 3 patients that had FVL mutation, of which 1 also had PT mutation.Conclusion: We did not observe a relationship between thrombosis, and FVL or PT mutations in CMPD patients; however, 3 of the patients that had hepatic vein thrombosis also had FVL mutation.Larger studies are needed to more clearly determine if all CMPD patients with hepatic vein thrombosis need be investigated for FVL and PT mutation.
🔬Design:Research Article
📍Scope:2009 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: The aim of this study was to examine Factor V G1691A (Leiden) (FVL) and prothrombin G20210A (PT) gene mutation status, and their relationship with thrombosis in patients with chronic myeloproliferative disorders (CMPDs). Materials and Methods: The study included 160 patients with a CMPD that were regularly followed-up between 1993 and 2009. FVL and PT mutation status was established based on blood samples analyzed via PCR using specific primers. Results: The frequency of FVL and PT mutation was 12.5% and 4.4%, respectively. In total, 27 episodes of thrombosis occurred in 24 (15%) of the patients, and there wasn t an association between the observed thrombotic events, and FVL or PT mutations. Hepatic vein thrombosis was noted in 3 patients that had FVL mutation, of which 1 also had PT mutation.Conclusion: We did not observe a relationship between thrombosis, and FVL or PT mutations in CMPD patients; however, 3 of the patients that had hepatic vein thrombosis also had FVL mutation.Larger studies are needed to more clearly determine if all CMPD patients with hepatic vein thrombosis need be investigated for FVL and PT mutation.

Özet

Amaç: Bu çalışmanın amacı, kronik myeloproliferatif hastalık (KMPH) tanılı hastalarda Factor V G1691A (Leiden) (FVL) ve protrombin (PT) gen mutasyonu durumunu ve bunların trombotik komplikasyonlarla ilişkisini değerlendirmektir. Yöntemler ve Gereçler: 1993-2009 yılları arasında düzenli olarak takip edilen 160 KMPH hastası çalışmaya alındı. FVL ve PT mutasyon durumunu saptamak için kan örnekleri toplandı ve spesifik primerler kullanılarak PCR ile değerlendirildi.Bulgular: FVL ve PT mutasyonu sıklığı sırasıyla %12.5 ve %4.4 olarak bulundu. 24 hastada (%15)toplam 27 tromboz atağı saptandı ve bu mutasyonlarla tromboz gelişimi arasında herhangi bir ilişki gösterilemedi. FVL mutasyonu olan hastaların 3ünde hepatik ven trombozu saptandı ve 3 hastanın 1inde PT mutasyonu da vardı. Sonuç: TKMPHlı hastalarda FVL ve PT mutasyonu ile tromboz arasında herhangi bir ilişki gösterilemedi. Ancak, biz FVL mutasyonu olan hepatik ven trombozlu 3 KMPH hastası saptadık. Hepatik ventrombozlu tüm KMPH hastalarında FVL ve PT mutasyonu bakılmasına gerek olup olmadığını saptamak için büyük çalışmalara ihtiyaç olduğu gözükmektedir.

🔖

Cite This Article

SOYER, N., KÜÇÜKARSLAN, A. Ş., ŞAHİN, F., ÇEKDEMİR, D., KOSOVA, B., EROĞLU, F. Z., TÖBÜ, M., TOMBULOĞLU, M., ÇAĞIRGAN, S., DÖNMEZ, A., VURAL, F., SAYDAM, G. (2011). Kronik myeloproliferatif hastalık tanılı hastalarda Factor V 1691A (Leiden) ve protrombin G20210A gen mutasyonu ve tromboz. Turkish Journal of Hematology, Cilt: 28 - Sayı: 4, 306–311. https://ajindex.com/articles/413153

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005;128:275-90. [CrossRef] Cervantes F, Alvarez-Larrán A, Arellano-Rodrigo E, Granell M, Domingo A, Montserrat E. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institu- tion. Leukemia 2006;20:55-60. [CrossRef] Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G, Barosi G. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010;115:778-82. [CrossRef] Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 2005;86:91-9. [CrossRef] Vicente V, González-Conejero R, Rivera J, Corral J. The prothrombin gene variant 20210A in venous and arterial thromboembolism. Haematologica 1999;84:356-62.
  2. Gurgey A, Mesci L, Renda Y, Olcay L, Kocak N, Erdem G. Factor V Q 506 mutation in children with thrombo- sis. Am J Hematol 1996;53:37-9. [CrossRef] Akar N, Akar E, Dalgin G, Sözüöz A, Omürlü K, Cin S. Frequency of Factor V (1691 G --> A) mutation in Turkish population. Thromb Haemost 1997;78:1527-8.
  3. Akar N, Misirlioglu M, Akar E, Avcu F, Yalçin A, Sözüöz A. Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Hematol 1998;58:249. [CrossRef] Gürgey A, Hicsönmez G, Parlak H, Balta G, Celiker A. Prothrombin gene 20210 G-A mutation in Turkish patients with thrombosis. Am J Hematol 1998;59:79-80. Akar N. Factor V 1691 G-A mutation distribution in a healthy Turkish population. Turk J Hematol 2009;26:9-11.
  4. Ruggeri M, Gisslinger H, Tosetto A, Rintelen C, Mannhalter C, Pabinger I, Heis N, Castaman G, Missiaglia E, Lechner K, Rodeghiero F. Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia. Am J Hematol 2002;71:1-6. [CrossRef] Afshar-Kharghan V, López JA, Gray LA, Padilla A, Borthakur G, Roberts SC, Pruthi RK, Tefferi A. Hemostatic gene polymorphisms and the prevalence of thrombotic complications in polycythemia vera and essential thrombocythemia. Blood Coagul Fibrinolysis 2004;15:21-4. [CrossRef] Amitrano L, Guardascione MA, Ames PR, Margaglione M, Antinolfi I, Iannaccone L, Annunziata M, Ferrara F, Brancaccio V, Balzano A. Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with spl